TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06623266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neck management
Description: In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.~In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Neck management
Description: In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.~In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.
Study: NCT06676878

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental exercise
Description: A graded exercise test will be performed on a treadmill. After 3 minutes of standing on the treadmill, participants will walk at a speed of 4 km/h for the first 3 minutes, then the speed will be increased to 8 km/h. After this point, the treadmill speed will be increased by 2 km/h every 3 minutes until voluntary exhaustion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incremental exercise
Description: A graded exercise test will be performed on a treadmill. After 3 minutes of standing on the treadmill, participants will walk at a speed of 4 km/h for the first 3 minutes, then the speed will be increased to 8 km/h. After this point, the treadmill speed will be increased by 2 km/h every 3 minutes until voluntary exhaustion.
Study: NCT06685120

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP + HA injection
Description: Following autologous PRP harvesting and production, 5 mL of PRP and 40 mg/2 mL of HA will be infiltrated into the knee joint affected by gonarthrosis. The combined procedure will be performed by first infiltrating the hyaluronic acid, and next, leaving the needle inserted into the joint to avoid a second needle insertion, the PRP will be infiltrated, respecting the conditions of sterility. In this way, the two products will not be mixed in the same syringe.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Following autologous PRP harvesting and production, patients randomized into control group 1 will undergo single intra-articular PRP infiltration. Five mL of PRP will be infiltrated into the knee joint affected by gonarthrosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA injection
Description: Patients randomized into control group 2, will undergo similar blood sampling as the PRP+ HA group and the PRP group to maintain blinding. They will then undergo intra-articular infiltration of 40 mg/ 2 ml HA into the knee with gonarthrosis.
Study: NCT06682637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Pepaxti 20 mg powder for concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution
Study: NCT06684678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized automatic coaching message for glycemic management and depressive symptom
Description: For 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management.
Study: NCT06690203

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: NRICM102
Description: A traditional Chinese medicine formula

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: NRICM102
Description: A traditional Chinese medicine formula
Study: NCT06687551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib (LY3009104) 4 mg
Description: Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib 200mg/day
Description: Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Description: Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day
Study: NCT06387433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile app use
Description: The experimental group will use the mobile application while controlled group will not use mobile application. Investigators will assess the effectiveness of mobile application in ensuring medication adherence and self-management among diabetics in Pakistan
Study: NCT06687551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 MG
Description: Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib (LY3009104) 4 mg
Description: use of JAK inhibitor at full dose until the end of the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgotinib 200mg/day
Description: use of JAK inhibitor at full dose until the end of the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 mg twice daily
Description: use of JAK inhibitor at full dose until the end of the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib 15 MG
Description: use of JAK inhibitor at full dose until the end of the protocol
Study: NCT06688721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Driving a bus equipped with EDA
Description: Eco-driving assistance (EDA) systems is a technology integrated into vehicles that helps drivers to optimize fuel efficiency and reduce emissions by providing real-time feedback and guidance on driving behaviors. The system typically analyzes several driving behaviours that are measured using different captors and sensors. These systems aim to reduce the overall carbon footprint of driving, leading to cost savings for the public transport company and reduced environmental impact.
Study: NCT06691802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shu Fei Tie
Description: Optimize the extraction process and matrix formulation, and combine the use of traditional Chinese medicine volatile oil and chemical transdermal enhancers to develop adermal patch（Shu Fei Tie）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shu Fei Tie placebo
Description: Shu Fei Tie Placebos are made using substances without active drug ingredients, following the same preparation procedures
Study: NCT06686004

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carrots
Description: Detection of polyacetylene and carotenoids in human biofluids

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carrots
Description: Detection of polyacetylene and carotenoids in human biofluids
Study: NCT06691295

Intervention type: OTHER
Intervention: Questionnaires
Description: This study aims to explore transdiagnostic psychological processes (PP) via the administration of self-reported scales and questionnaires, in a population of newly diagnosed FND patients, prior to any therapeutic management.~The main objective is to describe the psychometric properties (scores on tools measuring psychological processes) of NFT patients (presenting the main phenotypes; sensitivo-motor; and seizures and discomfort).
Study: NCT06687213

Intervention type: BEHAVIORAL
Intervention: Smoking cessation counselling group
Description: Case group will be counseled to cessate smoking and will be followed up with HbA1c
Study: NCT06686264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability group A
Description: Abdominal hollowing in supine (10 reps \& 2 sets) Single leg bridge (10 reps \& 2 sets), 3 session per week for 6 weeks Prone Single leg raise(10 reps \& 2 sets) Double leg bridge (10 reps \& 2 sets) Abdominal hallowing in 4 point kneeling(10 reps \& 2 sets), Complete Back stretch Pelvic rotations Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional exercises group B
Description: Complete Back stretch Pelvic rotations, 3 sessions per week for 6 week Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
Study: NCT06690021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine
Study: NCT05497960

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vivo workout
Description: 2 days a week for 12 weeks of a live, interactive virtual strength training program. Each class is 45 minutes long and lead by a certified trainer.
Study: NCT06695364

Intervention type: OTHER
Group type: OTHER
Intervention: survey study
Description: Not all classes were included in the study
Study: NCT06694077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Dexamethasone
Description: bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine only
Description: bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline
Study: NCT06694987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Physician Health Worker
Description: NPHW will aid participants in accessing a family doctor if required. The family doctor will receive a letter from the study, with suggested medication, based on the HOPE-4 algorithm. The family doctor may decide not to prescribe the recommended treatment or give another treatment (medication). In such case, the participant will still be part of the study and family physician's decision and reason why will be recorded. Follow-up will occur as per the visit schedule. All participants will attend a 20-minute follow-up visits in person at 0, 6 and 12 months, and via telephone at 3 and 9 months.~Participants will be assessed to determine if: i. the patient was assessed by their family physician, ii. the family doctor initiated recommended medication treatment(s), iii. they are adhering to the medications as prescribed, iv. they implemented what the NPHW has recommended about dietary and lifestyle changes, using the specific, measurable, achivable, relevant, time-bound (SMART) for goals.
Study: NCT06694181

Intervention type: OTHER
Intervention: AI-PERSONALIZED CLINICAL DECISION SUPPORT
Description: AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT

Intervention type: OTHER
Intervention: AI-PERSONALIZED CLINICAL DECISION SUPPORT
Description: AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT

Intervention type: OTHER
Intervention: AI-PERSONALIZED CLINICAL DECISION SUPPORT
Description: AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT
Study: NCT06695208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: biodentine used in socket preservation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: biodentine used in socket preservation
Study: NCT06695039

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluoroestradiol (18F)
Description: images for 90 minutes after F-18 FES injection
Study: NCT06694662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU EASY Microtabs Plus
Description: PKU EASY Microtabs Plus is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in patients from 3 years of age upwards.~PKU EASY Microtabs Plus is a microtablet form, slow-release, phenylalanine-free protein substitute containing a blend of essential and non-essential amino acids, vitamins, minerals and trace elements.
Study: NCT06691490

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: cTBS over SMA and cTBS over precuneus (control site)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Sham
Description: cTBS over SMA and cTBS over precuneus (control site)
Study: NCT06690008

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental group
Description: SDF application

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: SDF application
Study: NCT06688903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based diabetes management and community-based health coaching
Description: All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.
Study: NCT06688110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gixam System
Description: Jubaan's Gixam System is designed to predict the likelihood of colorectal adenomas or SSL by using white light in the 400 to 720 nm range to capture ultra-high-definition images of the of the tongue and analyzing the spectral signature of the oral microbiome to predict the presence of colorectal adenomas or SSL with help of artificial intelligence (AI).
Study: NCT06691750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed suture
Description: Size 0 barbed absorbable monofilament suture with unidirectional spikes that includes a loop in one of its ends, not requiring knots.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional smooth suture
Description: Size 1 smooth multifilament absorbable polyglactin suture.
Study: NCT06687265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: one pill of 500 mg per os twice a day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one pill per os twice a day for 28 days.
Study: NCT06689007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Intervention
Description: The intervention employs four established implementation strategies according to the Expert Recommendations for Implementing Change: conduct educational meetings, provide ongoing consultation, provide technical assistance, and change physical structure and equipment. The first component is a six-week online course led by the PI that combines weekly pre-recorded lectures, hands-on activities, group mentoring sessions and a reflective assignment. The second component of the intervention is ensuring access to the equipment needed for FES. The third component of the intervention is access to the FES Toolkit.
Study: NCT06686095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Adductor canal block
Description: Adductor canal block procedure: The patient will be informed about the technique and consent will be obtained. The patient's hip will be slightly externally rotated, and an ultrasonography linear probe will be placed on the medial thigh, at the midpoint of the patella and vastus medialis. After locating the femoral artery at approximately 3-4 cm depth, if not visible, the artery can be traced distally from the inguinal region using Doppler mode. Once the vastus medialis and sartorius muscles are identified, the superficial femoral artery is centered at the midpoint of the sartorius muscle. The adductor canal roof, along with the saphenous and vastus medialis nerves, appears as hyperechoic structures. A needle is inserted in-plane, advancing toward the anterolateral femoral artery aspect, and 5-20 mL of LA is injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Genicular Nerve Block
Description: Genicular Nerve Block: The patient is informed and consent is obtained. With a pillow in the popliteal fossa, the knee is slightly flexed. For the superior lateral genicular nerve, a linear USG probe is positioned on the lateral femoral epicondyle, moving proximally to visualize the bone metaphysis. The superolateral artery is seen between the vastus lateralis fascia and the femur. Using in-plane or out-of-plane technique, the needle is guided to the bone, and 4-5 mL of LA is injected. For the superior medial nerve, the probe is placed on the medial epicondyle and moved proximally to visualize the bone near the adductor tubercle. The artery lies between the femur and vastus medialis fascia. For the inferomedial artery, the probe is placed on the tibial medial condyle, moving distally. A negative aspiration test is conducted before each LA injection.
Study: NCT06274138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: haptonomy
Description: Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
Study: NCT06119698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetActive+
Description: This is a 10-week group mind body program focused on improving self-reported physical activity, performance-based physical activity, and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increase in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
Study: NCT06213012

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Spinal cord Stimulation
Description: Delivered using a constant-current stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Spinal cord Stimulation
Description: Delivered using a constant-current stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Stimulation (ESS)
Description: The device used for ESS, the CoverEdgeX 32 Surgical Lead system (Boston Scientific, USA), is a device approved by the FDA used in the treatment of severe pain and is approved for individuals to manage chronic pain when other treatments have not been effective.~If you are in the ESS group, you will have surgery to have the stimulator placed and the stimulator will be removed at an office visit towards the end of the study.
Study: NCT05666700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent
Description: Cilta-cel is a cellular immunotherapy derived from autologous CD3+ T-cells that have undergone ex vivo modification to target B-Cell Maturation Antigen (BCMA) on the surface of plasma cells. Cilta-cel will be administered as two IV infusions, ≥70% unlabeled and ≤30% labelled. The dose will be based on the patient's weight (kg) at apheresis
Study: NCT06055959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Zilucoplan will be administered subcutaneously to pediatric study participants.
Study: NCT05812144

Intervention type: OTHER
Group type: OTHER
Intervention: Remote monitoring program
Description: Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
Study: NCT04877704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symprove (probiotic)
Description: Symprove's unique water-based formula is packed full of live, active bacteria. It is a probiotic, not a drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo to Symprove probiotic
Study: NCT06464679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR NK cells
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.
Study: NCT05480774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRG hard capsule
Description: Each subject was given orally 2 KRG hard capsules/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hard capsule
Description: Each subject was given orally 2 placebo hard capsules/day for 12 weeks
Study: NCT06274346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiangular Isometric exercise
Description: already were described in arm descriptions

Intervention type: OTHER
Group type: OTHER
Intervention: Multiangular Isometric exercise
Description: already were described in arm descriptions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiangular Isometric exercise
Description: already were described in arm descriptions
Study: NCT05331989

Intervention type: OTHER
Intervention: patient group/ healthy group
Description: Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index